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 Behçet’s disease (BD) is a chronic relapsing and remitting 
vasculitis of unknown aetiology. It has the capacity to affect 
almost all organ systems because of its potential to involve 
both arteries and veins of all sizes, resulting in signiﬁcant 
organ-threatening morbidity and mortality. Traditionally 
known as the ‘silk road’ disease, it has a worldwide occurrence. 
The aetiopathological mechanisms of disease development in 
BD remain poorly understood, but genome wide studies show 
human leukocyte antigen and non-human leukocyte antigen 
associations. Environmental inﬂuences and genetic factors 
may have a role in the aetiopathogenetic mechanisms that 
lead to development of the disease, indicating the autoimmune 
and auto-inﬂammatory nature of BD. The evidence base 
for treatment is limited but new knowledge is emerging and 
current treatment options range from symptomatic treatment, 
through to non-biological and biological immunosuppressive 
drugs, to cover the spectrum of clinical manifestations. 
 Introduction 
 Behçet’s disease (BD) is a rare but severely debilitating 
vasculitis, which typically manifests as mucocutaneous 
disease with orogenital ulcers and skin lesions; 1 however, 
involvement of the musculoskeletal system, eye, nervous 
system, gastrointestinal tract, vascular beds, urogenital tract 
and cardio-pulmonary system can lead to significant morbidity 
and mortality. 
 There is often a long delay between the onset of symptoms 
and diagnosis of BD because of the variable, and sometimes 
intermittent, symptoms, the need for exclusion of mimics, the 
lack of a specific blood test and marker for the disease and, 
sadly, a general lack of awareness of this condition. 
 Epidemiology 
 BD occurs worldwide but clusters are found mainly along the 
‘silk road’ with highest prevalence in Turkey (approximately 
80–370 cases per 100,000), 2 Japan and Iran, and lower 
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prevalence in North American and northern European 
populations. In the UK, there is an estimated 0.64 cases per 
100,000. 3 While the commonest age group affected is those 
aged 20–40 years, BD is also seen in children and older patients. 
Incidence is higher in males in the high prevalence areas of 
Turkey and Middle East, but sex distribution is variable in other 
counties. The disease is usually severe in young adult men. 
 BD is mainly sporadic, but clustering can occur in families. 
The aetiology remains unknown, but a combination of 
genetic and environmental factors may play a role. The 
 HLA-B51 genetic marker is found in around 60% of BD 
patients. 4 Genome-wide association studies (GWAS) have 
identified  HLA-B51 and  HLA ERAP1 (endoplasmic 
reticulum aminopeptidases) as BD susceptibility genes. 5–7 
Key points
Behçet’s disease is a chronic inﬂammatory disease of 
unknown aetiology that can affect all body organ systems 
because of inﬂammatory effects on arteries and veins of all 
sizes
Diseases that cause orogenital ulcerations have to be 
excluded by investigations before conﬁrming BD; sexual 
infections and inﬂammatory bowel diseases are the main 
mimics
Treatment is tailored to individual patient clinical 
manifestations and involves the use of various symptomatic 
measures and disease modifying non-biological and 
biological therapies
The use of anticoagulation in thrombosis is controversial 
and immunosuppressive therapy is recommended for 
management of venous and arterial thrombosis
Eye disease is common and needs careful assessment and 
treatment because of the high risk of visual loss
Multidisciplinary pharmacological and non-pharmacological 
management is vital
KEYWORDS: Behcet’s disease, biological drugs, disease-
modifying drugs, immunosuppression, vasculitis
CMJv17n1-CME_Nair.indd   71 09/01/17   7:17 PM
CME Rheumatology
72 © Royal College of Physicians 2017. All rights reserved.
In a susceptible individual, as yet unknown environmental 
factors, which may include microbial exposure and cellular 
and humoral immunity, play a pathogenic role. Pro-
inflammatory cytokine cascade, inflammatory responses, 
relapsing and remitting course and treatment responses to 
immunosuppressive medications in BD indicate the disease has 
an autoinflammatory-autoimmune nature. 
 Classiﬁcation criteria 
 The International Criteria for Behçet’s disease (ICBD), 8 
International Team for the Revision of the International 
Criteria for Behçet’s Disease (ITR-ICBD, 2013) 9 and the 
International Study Group criteria (Table 1) 10  are the 
classification criteria currently in use. The International Study 
Group criteria 10 are less sensitive but more specific than the 
ICBD criteria (Table  2 ) 8 and ITR-ICBD criteria. 9 A diagnosis 
of BD is made based on the clinical picture – defined by 
characteristic features after exclusion of relevant differential 
diagnoses by appropriate assessments and investigations. 
 Clinical manifestations 
 BD can affect potentially all organ systems because of its 
propensity to affect all arteries and veins. 
 Oral and genital ulcers are the hallmarks of the disease, 
seen in up to 97% and 60–90% of patients, respectively. The 
oral ulcers in BD are similar to the common benign recurrent 
aphthous stomatitis, can vary in size from minor (less than 
10 mm in size) to major (greater than 10 mm) to herpetiform 
ulcers (pin head to 1–3 mm), and may scar. Importantly, these 
ulcers are painful and may affect eating and swallowing. 
 Genital ulcers can affect any part of genitourinary tract and 
can scar. They are common in the scrotum in male patients 
and the vulva in female patients, and can take weeks to 
heal. Although BD does not affect fertility directly, painful 
recurrence of genital ulcerations in either males or females may 
limit the capacity for sexual intercourse. 
 It is important to exclude other causes of oral ulcers, such as 
infection, cyclical neutropenia, medication, inflammatory bowel 
disease (IBD), vitamin B12 deficiencies, rheumatic diseases (eg 
systemic lupus erythematosus), autoinflammatory diseases, 
PFAPA (periodic fever, aphthosis, pharyngitis and adenitis), 
Sweet’s syndrome and mimics, like bullous dermatosis. It is also 
important to exclude other possible causes of genital ulcerations: 
sexual infections, non-sexually acquired genital ulcerations 
(which may be reactive to infections), IBD, drug reactions, 
trauma and neoplasms. Complex aphthosis is a condition of oral 
and genital ulcers in the absence of other features of BD. Oral 
and genital ulcers also occur in MAGIC (mouth and genital 
ulcers with inflamed cartilage) syndrome, cyclical neutropenia 
and as adverse drug effects. 
 Cutaneous disease manifests with papulonodular 
lesions, erythema nodosum-like lesions, acneiform rashes, 
pseudofolliculitis, pyoderma gangenosum and occasionally 
erythema multiforme-like rashes. Pathergy, an eruption of 
a papulopustular lesion at the site of needle injury within 
24–48 hours, is not exclusive to BD – it also occurs in Sweet’s 
syndrome and pyoderma gangernosum. Cutaneous lesions may 
be commonly associated with arthritis in BD. 
 Gastrointestinal BD can feature ulceration throughout the 
tract, but mainly in the mouth, oesophagus, ileo-caecal and 
ascending colon, and may be indistinguishable from IBD. 
Diarrhoea, bleeding, abdominal pain and fever are common 
presenting features and, occasionally, complications like 
fistula and bowel perforation occur. Orofacial granulomatosis, 
intestinal biopsy showing granulomata and paper cut genital 
ulcers are suggestive of IBD. Endoscopic and radiological 
investigations will be required to map the disease. 
 Neuro-Behçet’s disease (NBD) is a serious complication, which 
affects up to 10% of patients and may cause parenchymal and 
non-parenchymal disease. 11 Parenchymal disease, which affects 
the cerebrum, brainstem, cerebellum and spinal cord, can result 
in intra-axial cranial neuropathy, ophthalmopresis, pyramidal 
disease, focal and multifocal cerebral lesions, and various 
brainstem syndromes depending on the extent of neuraxial 
involvement. Non-parenchymal disease includes cerebral venous 
sinus thrombosis, intracranial hypertension and meningitis, 
which may be recurrent. However, the commonest neurological 
symptom is migraine, which is similar to non-BD migraine. 
Radiological investigations, including magnetic resonance 
imaging (MRI), computerised tomography (CT), magnetic 
 Table 1.  The International Study Group criteria 
(1990) 10 
 Criteria  Features 
Recurrent oral ulcerations Minor aphthous, major aphthous 
or herpetiform ulceration observed 
by physician or patient, which 
recurred at least three times in 
one 12-month period
Plus any two of the following:
Recurrent genital ulceration Aphthous ulceration or scarring 
observed by physician or patient
Eye lesion Anterior uveitis, posterior uveitis 
or cells in vitreous on slit lamp 
examination or retinal vasculitis 
observed by ophthalmologist
Skin lesions Erythema nodosum observed 
by physician or patient, 
pseudofolliculitis or papulopustular 
lesions, or acneiform nodules 
observed by physician
Positive pathergy test Read by a physician at 24–48 hours.
 Table 2.  The International Criteria for Behçet’s 
disease (2006) 8 
 Symptom  Score* 
Genital aphthosis Two points
Ocular lesions Two points
Oral aphthosis One point
Skin lesions One point
Vascular lesions One point
Pathergy One point
 *3 or more points satisfy criteria for Behçet’s disease 
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resonance angiography (MRA), computerised tomographic 
venography (CTV), magnetic resonance venography (MRV), 
cerebrospinal fluid studies and electroencephalogram, might 
be required in appropriate cases. Magnetic resonance diffusion 
imaging with magnetic resonance spectroscopy may have a role 
in imaging in NBD but requires large studies to validate its use. 
 Vascular BD is unique in affecting both arterial and venous 
vascular system of all sizes and is a major cause of morbidity 
and mortality. The arterial disease is less prevalent than venous 
disease. Arterial lesions resulting from inflammation cause 
aneurysm, ulcerations, thrombosis and stenosis, whereas, the 
venous disease mainly manifests as venous thrombosis and 
thrombophlebitis. The thrombus is usually tightly adherent 
to the vessel wall and may not embolise. Appropriate imaging 
of the vascular system with Doppler ultrasound studies, CT, 
CTV, MRI, MRA and MRV will be necessary. CT angiography 
gives good anatomical details but has limited use in early large 
vessel disease and MRA provides details of structural changes 
but correlation with clinical disease activity is not always good. 
MRA may be useful for following up the structural changes in 
blood vessels, such as an increase or decrease in size of aneurysm 
after treatment, and may be preferred to computerised 
tomography angiography because of the lack of radiation risks. 
 18 F-fludeoxyglucose positron emission tomography with CT or 
magnetic resonance localisation may be useful in assessment of 
clinical disease activity as in other large vessel vasculitis but may 
be modified by immunosuppressive treatment. 
 Arthralgia is a common symptom in BD. Oligoarthritis, 
monoarthritis and polyarthritis can be indistinguishable from 
other inflammatory arthritis, like psoriatic or rheumatoid 
arthritis, but is usually non-erosive and non-deforming. 
Enthesial inflammation can sometimes be a predominant 
feature. Fibromyalgia is a common cause of pain in BD. 
 Eye disease in BD is a major cause for concern as, if inadequately 
treated, it represents a major cause of visual loss – particularly in 
young males. There is a spectrum of ocular manifestations (up 
to 70% of patients with BD are affected): anterior uveitis, pars 
planitis, posterior uveitis, retinal vasculitis, scleritis, episcleritis, 
thrombosis of retinal artery and vein and optic neuritis. BD may 
cause ocular pain, eye redness, visual disturbances, photophobia 
and an estimated visual loss of approximately 10–20% at 5 years. 12 
Visual charting (visual fields and LogMAR visual acuity scores), 
ophthalmological examination, optical coherence tomography 
and, occasionally, visual evoked potentials are essential for both 
diagnosing disease and monitoring response to therapy. 
 Pregnancy outcome is generally favourable with flares noted 
only in one in six pregnancies. There are some reports of 
miscarriage, 13 preterm labour and neonatal deaths but there is 
no evidence that this is different to a healthy population 14 or 
that BD affects fertility. A 2015 study showed that BD did not 
negatively influence feto-maternal outcome. 15 
 Hugh-Stovin syndrome, 16 symptoms for which can include 
fever, chest pain, deep vein thrombosis, thrombophlebitis and 
pulmonary aneurysms, may present like BD and it is as yet 
not known whether this syndrome correctly lies within the 
spectrum of BD. 
 Fatigue is a severe accompaniment of BD, similar to other 
inflammatory diseases. Unfortunately, fatigue does not always 
respond to successful treatment of the disease. 
 Uncommon manifestations of BD are listed in Box  1 . 
 Box 1.  Uncommon manifestations in Behçet’s 
disease 
 >  Cardiac – coronary vasculitis, pericarditis, myocarditis, 
endocarditis, coronary aneurysms, valvular disease and 
arrhythmias 
 >  Pulmonary – pulmonary opacities, haemorrhage, vasculitis, 
pleural effusions, pulmonary aneurysms, pulmonary 
hypertension and fibrosing mediastinitis 
 >  Renal – mild renal impairment, glomerulonephritis, interstitial 
nephritis, renal artery aneurysm and amyloidosis 
 >  Other associations – MAGIC (mouth and genital ulcers with 
inflamed cartilage) represents features of relapsing chondritis 
and mucosal ulcers 
 >  Sweet’s syndrome – fever, nodular rashes, and mouth and 
genital ulcers 
 Approach to the diagnosis 
 A careful history and examination of all relevant systems is 
required, with differential diagnoses excluded by appropriate 
investigations (Box  2 ). Particularly, other systemic rheumatic 
diseases (eg systemic lupus erythematosus), IBD, coeliac 
disease, drug exposure (methotrexate, nicorandil etc), sexually 
transmitted diseases (herpes virus, HIV, gonorrhoea, chlamydia 
etc) and non-sexually acquired infection-related ulcers, cyclical 
neutropenia, vitamin deficiencies (B12) and Sweet’s syndrome may 
present with manifestations that mimic BD. The confirmation of 
diagnosis is based on appropriate clinical symptoms, signs and 
exclusion of differential diagnoses. A multidisciplinary specialist 
assessment is mandatory to reach a diagnosis. 
 Management 
 Because of the complex nature of the disease and multisystem 
involvement, a holistic approach to management is required 
with involvement of relevant specialists. A combined 
pharmacological and non-pharmacological approach to 
management is essential, as for any chronic disease. With 
the absence of large randomised controlled clinical trials to 
evaluate the effects of various interventions in BD, treatment is 
driven by recommendations of expert bodies like EULAR, with 
consensus statements. 17 
 The basic tenet of treatment is to use the most effective and 
least toxic treatment. Various disease-modifying drugs used in 
BD are listed in Table  3 and the newer drugs, which need more 
evidence, are listed in Box  3 .  18–22 Mucosal ulcer treatment should 
reduce pain, duration of ulceration and ensure healing – plus, in 
the long term, suppress recurrence. Topical treatment provides 
mucosal barriers to promote healing. Oral hygiene and avoidance 
of sodium lauryl sulphate-containing toothpaste, an irritant, 
is important. Topical corticosteroids in various formulations 
are used. Betamethasone sodium phosphate 500 µg tablets 
or prednisolone 5 mg dissolved in 10–20 mL saline and held 
in the mouth for 3 minutes as a mouthwash, hydrocortisone 
oromucosal tablets applied close to the ulcer, and beclometasone 
dipropionate inhaler 50–100 µg sprayed twice daily on the 
oral mucosa are effective topical treatment of oral ulcers. The 
antibiotics tetracycline (250 mg in 10 mL of water) or doxycycline 
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 Genital aphthous ulcers are severely painful and should 
be treated with strong analgesics, topical anaesthetics (10% 
lidocaine spray or 2–5% gel), topical corticosteroid ointment 
(dermovate) or paste, oral corticosteroids and antibiotics in 
case of secondary infection of the genital ulcer. Intralesional 
steroids may be offered in intractable ulcers. Skin barrier can 
be maintained with emollients. General vulval care, avoiding 
soaps that can cause irritation of vulval mucosa and use of 
soap substitutes (dermol) are often reported to be useful by 
patients. Care should be taken to avoid injury to vulval and 
perineal skin to avoid the pathergy phenomenon, infection and 
pseudofolliculitis. 
(50–100 mg in 10 mL of water) used 3–4 times daily as mouthwash 
are particularly effective, suggesting a role of oral bacteria in ulcer 
pathogenesis. 
 Benzydamine hydrochloride 0.15% oral rinse (local 
analgesic), chlorhexidine mouthwash (anti-infective) and 
lidocaine spray or gel are useful adjuncts in symptom 
management. A meta-analysis of interventions for oral ulcers in 
BD failed to either confirm or refute the effectiveness of various 
interventions because of the paucity of good quality studies. 23 
 Table 3.  Disease modifying drugs (DMDs) used in 
Behçet’s disease 
 Oral DMDs  Dose of drug 
Azathioprine 
 Mycophenolate mofetil 
 Methotrexate 
 Tacrolimus 
 Ciclosporin 
 Sulfasalazine 
 Dapsone 
 Thalidomide (exceptional 
use) 
 Colchicine 
 Prednisolone
2–3 mg/kg/day 
 2–3 gram/day 
 20–25 mg/week 
 4–8 mg/day (depending on plasma 
trough levels) 
 2–5 mg/kg/day 
 2–3 g/day 
 2–3 mg/kg/day 
 50–300 mg/day 
 0.5–2 mg/day 
 Variable dose (depending on indication 
and stage of treatment)
 Parenteral treatment 
Cyclophosphamide 
 Anti-TNF α inhibitors 
 Infliximab 
 Adalimumab 
 Etanercept 
 Certolizumab 
 Rituximab 
 Interferon α 
 Alemtuzumab
15 mg/kg (vasculitis regimens) 
 5 mg/kg at 0, 2 and 6 weeks then once
every 8 weeks 
 40 mg every 2 weeks 
 50 mg/week 
 400 mg at 0, 2 and 4 weeks then once 
every 4 weeks 
 1 g at 0 and 2 weeks 
 Various regimens for Roferon A and 
pegylated interferon α 2b 
 3 mg (day 1), 10 mg (day 3), 30 mg 
(day 5), 30 mg (day 8), 30 mg (day 10) 
and 30 mg (day 12)
 Box 3.  Newer medications on the horizon (further 
evidence needed) 
 >  Apremilast – phosphodiesterase-4 inhibitor 18 
 >  Anakinra – interleukin (IL)-1 receptor antagonist 19 
 >  Canakinumab – human monoclonal immunoglobulin G1 
inhibitor of IL-1β 20 
 >  Tocilizumab – IL-6 inhibitor 21 
 >  Ustekinumab – IL-12/23 inhibitor 22 
 Box 2.  Investigations for Behçet's disease 
 Routine 
 >  Full blood count, renal, liver, bone profile 
 >  Inflammatory markers, including CRP and ESR 
 >  Urine analysis 
 >  Chest X-ray 
 >  Coeliac screen 
 >  Stool sample 
 >  Autoimmune screen 
 >  Coagulation profile and antiphospholipid antibodies 
 >  Mouth and genital ulcer swab and culture, occasionally eye swab 
 Other investigations that may be required 
 >  Oral disease – oral biopsy to exclude orofacial granulomatosis and 
bullous dermatosis (histology and direct immunofluorescence) 
 >  Genital disease – vulval biopsy to exclude mimics (eg lichen 
sclerosis) 
 >  Neuro and vascular BD – Doppler studies, CT or MRI brain 
and spinal cord, MRV/CTV, MRA or CTA to evaluate neurologic 
and vascular disease; CSF studies, EEG, EMG, NCS,  18 F fluoro-
2-deoxyglucose PET with CT/MRI localisation (for early 
inflammation in large vessel vasculitis) 
 >  Musculoskeletal BD – synovial fluid analysis, X-ray, ultrasound 
or MRI to evaluate joints 
 >  Skin BD – skin biopsy and immunofluorescence 
 >  Cardiac BD – electrocardiogram, echocardiogram 
 >  Chest CT – assess mediastinal diseases, fibrosing mediastinitis, 
aneurysms, pleural effusions, complications of venous 
thrombosis and collaterals 
 >  Gastrointestinal BD – stool sample for faecal calprotectin, 
endoscopy and biopsy 
 >  Ear, nose and throat disease: nasal endoscopy 
 >  Ocular BD – OCT, VEP, fluorescein angiogram, Schirmer’s test, 
intraocular fluid culture to exclude infections 
 >  Cystoscopy and kidney, urinary bladder CT for urological 
disease 
 BD = Behçet’s disease; CRP = C-reactive protein; CSF = cerebrospinal fluid; CT = 
computerised tomography; CTA = computerised tomography angiography; 
CTV = computerised tomographic venography; EEG = electroencephalogram; 
EMG = electromyography; ESR = erythrocyte sedimentation rate; MRA = 
magnetic resonance angiography; MRI = magnetic resonance imaging; MRV = 
magnetic resonance venography; NCS = nerve conduction study; OCT = optical 
coherence tomography; PET = positron emission tomography; VEP = visual 
evoked potentials 
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 Cutaneous lesions are treated topically with steroid creams and 
oral antibiotics such as lymecycline, which has anti-inflammatory 
properties. Erythema nodosum-like lesions usually respond to 
colchicine (0.5–2 mg/d, orally) and corticosteroids. Colchicine, 
which offers significant benefit in arthritis and mucocutaneous 
disease, exerts its anti-inflammatory activity by inhibiting 
neutrophil chemotaxis. 24 Non-responsive mucocutaneous 
disease requires escalation of treatment to non-biologic disease-
modifying drugs (DMDs). Pyoderma gangrenosum is intensely 
inflammatory and requires strong immunosuppression with 
steroids and DMDs. 
 Azathioprine (2–3 mg/kg/day orally), which inhibits DNA 
synthesis, is beneficial at doses higher than normally used in 
other rheumatic diseases. 25,26 Mycophenolate mofetil (MMF; 
2–3 gm/day orally) is an inhibitor of T- and B-lymphocytes. 
Dapsone (2–3 mg/kg/day), through its anti-inflammatory 
and bactericidal properties, has a role in cutaneous disease. 27 
Checking G6PD deficiency is important prior to dapsone use, to 
avoid haemolysis. TNF-α 28–34 and interferon α 35–40 are potent 
biological drugs used in resistant mucocutaneous disease. 
Thalidomide, 41 a TNF inhibitor, is now used only in exceptional 
circumstances (if other DMDs and/or biologics have failed), but 
needs extremely careful monitoring because of its very narrow 
therapeutic index. Nerve conduction studies must be performed 
at baseline and then serially and after each dose change of 
thalidomide to detect potential neurotoxicity; the drug should 
be immediately discontinued if symptoms suggesting peripheral 
neuropathy are reported. Women of childbearing age must have 
pregnancy excluded prior to its use and agree to use foolproof 
contraception, with regular pregnancy tests while on the drug. 
 Musculoskeletal symptoms are managed with various 
analgesia, including non-steroidal anti-inflammatory 
drugs (where appropriate), as well as physical therapy. The 
inflammatory symptoms are suppressed with oral DMDs, 
escalating to biologics (typically TNF inhibitors). Fibromyalgia 
is frequently observed in BD. It requires an approach of 
graded physical activity, pain-modifying medications 
(eg amitriptyline, pregabalin) and cognitive behavioural 
therapy. Enthesial inflammation may be amenable to local 
steroid injections and physical therapy and, if not, DMDs. 
 Inflammatory eye disease must be managed in partnership 
with an experienced ophthalmologist. Treatment involves 
tailoring therapy to the site of disease and impending threat 
of visual loss. Anterior uveitis is treated with topical steroids, 
cycloplegics and mydriatics with addition of oral steroids 40 mg 
average for 4–6 weeks and extending to 3 months if required. 
Posterior uveitis is suppressed with steroids and DMDs like 
azathioprine (used in higher doses than other rheumatic 
diseases, 2.5–3 mg/kg) or ciclosporin; 42 MMF may be used 
as a second-line drug with beneficial effects noted in cystoid 
macular oedema. Retinal vasculitis is aggressively treated 
with steroids (intravenous, oral, intraocular) and DMDs. For 
resistant and/or aggressive disease, rapid escalation to biologics 
therapy with infliximab (5 mg/kg at 0, 2 and 6 weeks then once 
every 6 weeks thereafter) or interferon alpha, which is a potent 
drug; DMDs should be bypassed if indicated. Refractory disease 
is managed with rituximab 43 or alemtuzumab. 
 Vascular BD is treated with DMDs and steroids. The arterial 
aneurysm requires strong immunosuppressants. Intravenous 
steroids (three pulses of 1,000 mg methylprednisolone) followed 
by oral steroids and cyclophosphamide are used to rapidly 
control the disease. Oral DMDs (azathioprine) can be used 
6 months after induction with cyclophosphamide. Alternatively, 
TNF inhibitors can be used in place of cyclophosphamide. 
 Enlarging arterial aneurysm is an emergency that will 
necessitate consideration of endovascular repair to avert 
rupture or pressure effect. 44,45 Open surgical repair carries 
a high risk of morbidity and mortality and is complicated 
by the formation of pseudoaneurysms. 46 All surgical and 
endovascular interventions should be supported with heavy 
immunosuppression. Expert opinion is divided on the 
treatment of deep venous thrombosis and cerebral venous 
sinus thrombosis: some experts recommend anticoagulation, 
while others believe that effective immunosuppression is key. 17 
A 2015 observational study did not show any favourable effect 
from the addition of anticoagulation to immunosuppresion 
on the relapse rates of vascular events in BD. 47 We strongly 
advocate intense immunosuppression, which is required to 
reduce the stimulus for thrombosis and do not recommend 
anticoagulation, unless detailed vascular imaging has excluded 
the presence of arterial aneurysms. However, anticoagulation 
may be indicated in the presence of another pro-thrombotic 
condition (eg Protein C and S resistance, Factor V Leiden) but, 
again, coexisting arterial aneurysms must be excluded. Stenotic 
arterial lesions require stenting to help re-establish perfusion. 
Pulmonary aneurysms can be coiled and bleeding vessels 
embolised. Bronchial artery embolisation is frequently required 
as it is the commonest cause of bleeding and haemoptysis. 
 Neuro BD (parenchymal and non-parenchymal) is managed 
with strong immunosuppression, as with other systemic 
involvement in BD. 11 Intravenous cyclophosphamide along with 
high-dose intravenous methylprednisolone (1 g daily for 3 days) 
followed by oral corticosteroids can be used in neurovascular 
diseases prior to TNF inhibitors, but ciclosporin is generally 
avoided. The sequelae of neurological damage require 
physical therapy and neuro-cognitive assessment and support. 
Management of migraine is similar to subjects without BD. This 
requires lifestyle changes like good hydration, sleep hygiene, 
dietary modifications and medications (acute medications like 
triptans and preventatives such as propranolol, nortriptyline 
or topiramate). 
 Gastrointestinal BD presents like IBD and is treated similarly 
with immunosuppresssion with local and oral steroids and both 
non-biological (salazopyrin or azathioprine) and biological 
DMDs. The complications of perforation and fistulation require 
surgical intervention supported by strong immunosuppression. 
 A head-to-head trial (BIO BEHCET’S) of infliximab with 
interferon α is underway, 48 which will demonstrate the 
positional hierarchy of the above treatment in BD and also 
provide important genetic and biomarker clues to BD. 48 
 In pregnancy, cyclophosphamide, methotrexate, MMF 
and thalidomide are contraindicated. Although we do not 
recommend colchicine, studies have not shown adverse 
outcomes. 49 The safety of biological agents in BD pregnancy 
is extrapolated from its use in other rheumatic diseases and 
balanced against risk-benefit considerations. Use of biologic 
agents other than TNF inhibitors in BD is not well known. 
Non-steroidal anti-inflammatory drugs should be avoided 
in the third trimester of pregnancy because of the risk of 
premature closure of the patent ductus arteriosus. 
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 Hematopoietic stem cell transplantation has been used with 
success in severe BD that had not responded to non-biological 
and biological DMDs 50,51 and the European Bone Marrow 
Transplant registry ( www.ebmt.org ) has data on its use and 
benefits. 52 
 Measurement of the disease activity with disease-specific 
measures (Behçet’s Disease Current Activity Form (BDCAF) 53 
and the Leeds BD-quality of life (BD-QoL) 54 ) and organ-specific 
measures and impact scores (Oral Ulcer Activity Index, 55 The 
Expanded Disability Status Scale, the modified Rankin scale 56 
and neuro-Behçet’s disability score) is important. Quality of 
life measures like the health assessment questionnaire disability 
index, short form health survey 36 and the EQ-5D-5L are 
important to assess the impact of disease and the effects of 
intervention. 
 Prognosis 
 The impact of BD is significant, with effects on somatic and 
psychosocial wellbeing. The organ-specific morbidity is high 
and arterial disease influences mortality. 57 While there is no 
direct effect on fertility, the influence of genital ulcerations and 
psychological stress is immense. The patient’s ability to work is 
also adversely influenced in BD. 
 Follow-up 
 Patients with BD should be offered a multidisciplinary 
assessment and management plan. Furthermore, follow-up 
under a physician with guidance from a specialist centre 
will be important for overview of disease and management. 
Organ-specific flares will require relevant specialist input. 
Patients should be encouraged to play a large role in self-care, 
which is important in chronic conditions. Relevant input from 
allied specialties, like physical and occupational therapists, 
psychologists and social support workers, is vital. 
 Conclusions 
 BD is a chronic, relapsing vasculitis with potential to affect 
all body systems with profound effects, causing considerable 
morbidity and mortality. There is a delay in diagnosis because 
of variable symptoms and a lack of valid biomarkers. A number 
of biomarkers have been described but none have proven to be 
reliable or valid for application in clinical practice for diagnosis, 
assessment of disease activity and monitoring. The research 
agenda for BD is huge, as so little is known. This ranges from 
basic science explorations into the potential pathophysiological 
mechanisms underlying the disease (if we don’t know the cause, 
it’s not surprising that treatment is not that good), through a 
better phenotyping of the clinical situation to more effective 
treatment. On the treatment side, there are two pressing issues:
 1 knowing how and when treatment, especially with biologics, 
can be de-escalated or stopped 
 2 the development of biomarkers allowing a personalised 
medicines approach to therapy. 
 Finally, the other major research agenda is the development 
of an effective disease activity score and enhanced patient-
reported outcome tool. There is a large unmet need for novel 
therapy in BD, which will hopefully become available as the 
aetiopathogenetic mechanisms are unlocked. ■ 
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